Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-11-17 00:00:00 ET · period of report 2023-11-15 · accession 0001209191-23-055846 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-17 | 2023-11-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $7.18 | -5,378 | 413.4K | -1% | -$38.6K |
| D | 2023-11-17 | 2023-11-16 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $6.76 | -3,000 | 413.4K | -0.7% | -$20.3K |
| D | 2023-11-17 | 2023-11-16 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 416.4K | +0.7% | +$3,180 |
| D | 2023-11-17 | 2023-11-16 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $0.00 | -3,000 | 520.0K | -0.6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-15 | F | D | 5,378 | $7.18 | 413,404 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-11-16 | S | D | 3,000 | $6.76 | 413,404 | D | — | — | (F3) The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.61 to $7.18 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. |
| 3 | Common | Class A Common Stock | 2023-11-16 | M | A | 3,000 | $1.06 | 416,404 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-11-16 | M | D | 3,000 | $0.00 | 520,000 | D | $1.06 · — to 2028-07-22 | 3,000 Class A Common Stock | (F5) Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |